title: Tumour-necrosis-factor antibody treatment in Crohn's disease.
authors.forename: B
authors.initials: B
authors.lastname: Derkx
authors.forename: J
authors.initials: J
authors.lastname: Taminiau
authors.forename: S
authors.initials: S
authors.lastname: Radema
authors.forename: A
authors.initials: A
authors.lastname: Stronkhorst
authors.forename: C
authors.initials: C
authors.lastname: Wortel
authors.forename: G
authors.initials: G
authors.lastname: Tytgat
authors.forename: S
authors.initials: S
authors.lastname: van Deventer
mesh_terms: D000636:Aminosalicylic Acids / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001379:Azathioprine / Q000627:therapeutic use; D002648:Child; D003424:Crohn Disease / Q000188:drug therapy / Q000276:immunology / Q000628:therapy*; D005260:Female; D006801:Humans; D019804:Mesalamine; D011241:Prednisone / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology*
chemical_list: D000636:Aminosalicylic Acids; D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D019804:Mesalamine; D001379:Azathioprine; D011241:Prednisone